AXL is a logical molecular target in head and neck squamous cell carcinoma

PURPOSE: Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard of care treatments for HNSCC patients include surgery, radiation and chemotherapy. Additionally, the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab is o...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Brand, Toni M., Iida, Mari, Stein, Andrew P., Corrigan, Kelsey L., Braverman, Cara M., Coan, John, Pearson, Hannah E., Bahrar, Harsh, Fowler, Tyler L., Bednarz, Bryan P., Saha, Sandeep, Yang, David, Gill, Parkash S., Lingen, Mark W., Saloura, Vassiliki, Villaflor, Victoria M., Salgia, Ravi, Kimple, Randall J., Wheeler, Deric L.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5032632/
https://ncbi.nlm.nih.gov/pubmed/25767293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2648
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items